Clinical trials: Advanced Sarcoma, open to volunteers
Desmoplastic Small Round Cell Tumor
Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS
Patients participating in this study have DSRCT that has spread locally or to other parts of the body and can no longer be surgically removed without causing significant harm.
- Trial name
- ISG-TULIPS (NCT07328425)
- Testing
- Lurbinectedin, Irinotecan
- Where
- 11 sites in Italy, Spain
- Volunteers
- 20 people
- Sponsor
- Italian Sarcoma Group
Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of…
- Conditions
- Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma
- Trial name
- NCT06498648
- Testing
- Abemaciclib, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Sarcoma
A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma
Phase I, open label, prospective, single-center, non-randomized, dose escalation clinical trial aiming to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of systemic transduced donor-derived NKG2D-CAR…
- Trial name
- CAR4SAR (NCT06087341)
- Testing
- NKG2D-CAR memory T cell
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Antonio Pérez Martínez
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Sarcoma, HER-2 Protein Overexpression
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this…
- Conditions
- Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma
- Trial name
- NCT04995003
- Testing
- T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Ewing's Sarcoma
A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma
This study is a randomized, controlled, multicenter, prospective clinical trial with a planned enrollment of 74 patients, who will be randomly assigned in a 2:1 ratio.
- Trial name
- NCT07092306
- Testing
- Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT), Irinotecan Combined with Temozolomide and Vincristine (VIT)
- Volunteers
- 74 people
- Sponsor
- Tang Xiaodong
Bone and Soft Tissue Tumors
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period.
- Trial name
- NCT06939855
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Solid Tumor, Sarcoma
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell…
- Conditions
- Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT06975293
- Testing
- STC-15 in combination with toripalimab, STC-15 monotherapy
- Where
- 14 sites in United States
- Volunteers
- 107 people
- Sponsor
- STORM Therapeutics LTD
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)
First-line Treatment of Advanced/unresectable DDLPS
Evaluating the efficacy and safety of liposomal doxorubicin hydrochloride and apatinib in combination with camrelizumab for the first-line treatment of advanced/unresectable dedifferentiated liposarcoma
- Trial name
- NCT06694324
- Testing
- Liposomal Doxorubicin (Doxil), Apatinib, Camrelizumab
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Fudan University
Soft Tissue Sarcoma
Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT)
Intervention prospective monocentric one arm study on the use of neoadjuvant radiotherapy with simultaneous integrated boost (Simultaneous Integrated Boost, SIB) in patients with STS with indication for preoperative radiotherapy.
- Trial name
- SPRINT (NCT05761054)
- Testing
- RT
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Malignant Neoplasm
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog…
- Trial name
- NCT07252739
- Testing
- MK-1084, Pembrolizumab, Cetuximab
- Where
- 39 sites in United States, Chile and 11 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Carcinoma, Breast Neoplasms
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
This prospective phase Il study is aim to evaluate the efficacy and safety of FGFR inhibitor combined with immune checkpoint inhibitors in FGFR1/2/3 variant advanced solid tumors.
- Conditions
- Urothelial Carcinoma, Breast Neoplasms, Lung Cancer, Gastric Cancer
- Trial name
- NCT06551896
- Testing
- Pemigatinib
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Cancer, Ovarian Carcinoma
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
This is a multicenter, open-label Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of sequentially administered CD146-targeted and GPC3-targeted CAR-T cell therapy in patients with advanced relapsed or…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovarian Sarcoma, Ovarian Cancer Stage IV
- Trial name
- BAH2573-104 (NCT07067255)
- Testing
- GPC3 CD146 CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Essen Biotech
Leiomyosarcoma
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
- Trial name
- TAGGED (NCT04535271)
- Testing
- Trabectedin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Sarcoma, Soft-tissue, Sarcoma
BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas
A Phase 1b, non-randomized, single-institution trial designed to assess the safety, tolerability and the highest dose with acceptable toxicity (RP2D) of BOLD-100 in combination with doxorubicin in patients diagnosed with advanced…
- Conditions
- Sarcoma, Soft-tissue, Sarcoma, Sarcoma,Soft Tissue, Sarcomas
- Trial name
- NCT07027423
- Testing
- BOLD-100, Doxorubicin 75 mg/m^2
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University Health Network, Toronto
Effectiveness, Sexuality
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.
- Trial name
- NCT05617859
- Testing
- Lenvatinib mesylate capsule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center